disopyramide has been researched along with Cardiac Failure in 28 studies
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of intravenously administered disopyramide phosphate were evaluated in seven patients with refractory ventricular tachycardia." | 9.04 | Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia. ( Mason, DT; Miller, RR; Vera, Z; Vismara, LA, 1977) |
| "These previously unrecognized immunomodulatory effects of amiodarone may contribute to its beneficial effects in heart failure patients." | 7.69 | Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure. ( Matsumori, A; Nishio, R; Nose, Y; Ono, K; Sasayama, S, 1997) |
| "A patient with ischemic cardiomyopathy and congestive heart failure was treated with disopyramide phosphate for ventricular arrhythmias." | 7.66 | Disopyramide-induced ventricular tachycardia. ( Gantz, KB; Lo, KS; Lucchesi, BR; Pitt, B; Stetson, PL, 1980) |
| "The parmacokinetics of disopyramide (DP) in 10 patients with imminent to moderate cardiac failure has been studied and compared with the results in normal volunteers." | 7.66 | Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure. ( Amlie, JP; Bredesen, JE; Landmark, K; Simonsen, S; Thaulow, E, 1981) |
| "The haemodynamic effects of disopyramide have been studied in 11 patients with manifest or imminent heart failure." | 7.65 | Haemodynamic effects of intravenous disopyramide in heart failure. ( Jensen, G; Sigurd, B; Uhrenholt, A, 1975) |
| "The management of syncope is clinically important for heart failure (HF) patients." | 5.72 | [Evaluation of Disopyramide Efficacy for Refractory Syncope in Heart Failure with Preserved Ejection Fraction Using Holter Electrocardiography: A Case Report]. ( Asai, Y; Sato, Y; Shintani, T; Yamamoto, T, 2022) |
| " The suggested dosage regimen of disopyramide seems to result in a satisfactory response." | 5.27 | Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure. ( Angelo, HR; Bonde, J; Bødtker, S; Kampmann, JP; Svendsen, TL, 1985) |
| "The effects of intravenously administered disopyramide phosphate were evaluated in seven patients with refractory ventricular tachycardia." | 5.04 | Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia. ( Mason, DT; Miller, RR; Vera, Z; Vismara, LA, 1977) |
| "These previously unrecognized immunomodulatory effects of amiodarone may contribute to its beneficial effects in heart failure patients." | 3.69 | Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure. ( Matsumori, A; Nishio, R; Nose, Y; Ono, K; Sasayama, S, 1997) |
| "To study influence of congestive heart failure (CHF) and acute myocardial infarction (AMI) on alpha 1-acid glycoprotein (AGP) and sialic acid (SA) concentration, and binding of AGP to disopyramide (Dis)." | 3.69 | Serum alpha 1-acid glycoprotein, sialic acid, and protein binding of disopyramide in normal subjects and cardiac patients. ( Chu, JS; Kishion, S; Miyazaki, K; Nomura, A, 1997) |
| "The pharmacokinetics and bioavailability of total (bound plus unbound) and unbound disopyramide were compared following the simultaneous administration of an oral dose of disopyramide and an intravenous dose of 14C-disopyramide in five normal volunteers and in 11 patients with congestive heart failure." | 3.67 | Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide. ( Haughey, DB; Leier, CV; Lima, JJ, 1984) |
| "A patient with ischemic cardiomyopathy and congestive heart failure was treated with disopyramide phosphate for ventricular arrhythmias." | 3.66 | Disopyramide-induced ventricular tachycardia. ( Gantz, KB; Lo, KS; Lucchesi, BR; Pitt, B; Stetson, PL, 1980) |
| "The parmacokinetics of disopyramide (DP) in 10 patients with imminent to moderate cardiac failure has been studied and compared with the results in normal volunteers." | 3.66 | Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure. ( Amlie, JP; Bredesen, JE; Landmark, K; Simonsen, S; Thaulow, E, 1981) |
| "The haemodynamic effects of disopyramide have been studied in 11 patients with manifest or imminent heart failure." | 3.65 | Haemodynamic effects of intravenous disopyramide in heart failure. ( Jensen, G; Sigurd, B; Uhrenholt, A, 1975) |
| " On the other hand, the elimination half-life of antiarrhythmic agents that have a large volume of distribution and are highly cleared by the liver may be twice as long in patients with CHF compared with normal subjects." | 2.37 | Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. ( Echt, DS; Roden, DM; Woosley, RL, 1986) |
| "The management of syncope is clinically important for heart failure (HF) patients." | 1.72 | [Evaluation of Disopyramide Efficacy for Refractory Syncope in Heart Failure with Preserved Ejection Fraction Using Holter Electrocardiography: A Case Report]. ( Asai, Y; Sato, Y; Shintani, T; Yamamoto, T, 2022) |
| "Milrinone (M) has been shown to improve left ventricular (LV) performance in animal and human studies." | 1.27 | Evaluation of the vasodilator vs inotropic effect of milrinone using an animal model of left ventricular failure: reversal of disopyramide depression of the myocardium with milrinone. ( Berdoff, R; Goldberg, E; Haimowitz, A; Spivack, G; Tay, S, 1987) |
| " The suggested dosage regimen of disopyramide seems to result in a satisfactory response." | 1.27 | Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure. ( Angelo, HR; Bonde, J; Bødtker, S; Kampmann, JP; Svendsen, TL, 1985) |
| "Underventilation and cardiac arrhythmias were observed only in the agonal phase after several minutes of circulatory arrest." | 1.26 | Cardiac consequences and treatment of disopyramide intoxication: experimental evaluation in dogs. ( Hayler, AM; Holt, DW; Medd, RK; O'Keeffe, B, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (75.00) | 18.7374 |
| 1990's | 4 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (3.57) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Asai, Y | 1 |
| Shintani, T | 1 |
| Yamamoto, T | 1 |
| Sato, Y | 1 |
| Owens, AT | 1 |
| Masri, A | 1 |
| Abraham, TP | 1 |
| Choudhury, L | 1 |
| Rader, F | 1 |
| Symanski, JD | 1 |
| Turer, AT | 1 |
| Wong, TC | 1 |
| Tower-Rader, A | 1 |
| Coats, CJ | 1 |
| Fifer, MA | 1 |
| Olivotto, I | 1 |
| Solomon, SD | 1 |
| Watkins, HC | 1 |
| Heitner, SB | 1 |
| Jacoby, DL | 1 |
| Kupfer, S | 1 |
| Malik, FI | 1 |
| Meng, L | 1 |
| Sohn, R | 1 |
| Wohltman, A | 1 |
| Maron, MS | 1 |
| Hamada, M | 1 |
| Ikeda, S | 1 |
| Shigematsu, Y | 1 |
| Theisen, K | 1 |
| Lo, KS | 1 |
| Gantz, KB | 1 |
| Stetson, PL | 1 |
| Lucchesi, BR | 1 |
| Pitt, B | 1 |
| Lima, JJ | 1 |
| Haughey, DB | 1 |
| Leier, CV | 1 |
| Swiryn, S | 1 |
| Bauernfeind, RA | 1 |
| Strasberg, B | 1 |
| Palileo, E | 1 |
| Iverson, N | 1 |
| Levy, PS | 1 |
| Rosen, KM | 1 |
| Landmark, K | 1 |
| Bredesen, JE | 1 |
| Thaulow, E | 1 |
| Simonsen, S | 1 |
| Amlie, JP | 1 |
| Desai, JM | 1 |
| Scheinman, MM | 1 |
| Hirschfeld, D | 1 |
| Gonzalez, R | 1 |
| Peters, RW | 1 |
| Kannelønning, KS | 1 |
| Podrid, PJ | 1 |
| Schoeneberger, A | 1 |
| Lown, B | 1 |
| Matsumori, A | 1 |
| Ono, K | 1 |
| Nishio, R | 1 |
| Nose, Y | 1 |
| Sasayama, S | 1 |
| Chu, JS | 1 |
| Kishion, S | 1 |
| Nomura, A | 2 |
| Miyazaki, K | 2 |
| Dreifus, LS | 1 |
| Nies, AS | 1 |
| Gal, J | 1 |
| Gerber, JG | 1 |
| Vismara, LA | 1 |
| Vera, Z | 1 |
| Miller, RR | 1 |
| Mason, DT | 1 |
| Story, JR | 1 |
| Abdulla, AM | 1 |
| Frank, MJ | 1 |
| O'Keeffe, B | 1 |
| Hayler, AM | 1 |
| Holt, DW | 1 |
| Medd, RK | 1 |
| Goldman, P | 1 |
| Ingelfinger, JA | 1 |
| Jutzy, RV | 1 |
| Pugh, DM | 1 |
| Jensen, G | 2 |
| Uhrenholt, A | 2 |
| Sigurd, B | 1 |
| Yasuda, H | 1 |
| Kobayashi, T | 1 |
| Kishino, S | 1 |
| Kohri, N | 1 |
| Iseki, K | 1 |
| Oźarek-Medyńska, T | 1 |
| Krynicki, M | 1 |
| Polubiec, A | 1 |
| Woosley, RL | 1 |
| Echt, DS | 1 |
| Roden, DM | 1 |
| Goldberg, E | 1 |
| Berdoff, R | 1 |
| Spivack, G | 1 |
| Haimowitz, A | 1 |
| Tay, S | 1 |
| Bonde, J | 1 |
| Angelo, HR | 1 |
| Bødtker, S | 1 |
| Svendsen, TL | 1 |
| Kampmann, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial[NCT02948998] | Phase 4 | 260 participants (Anticipated) | Interventional | 2018-05-14 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for disopyramide and Cardiac Failure
| Article | Year |
|---|---|
Advances in medical treatment of hypertrophic cardiomyopathy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Calcium Channel Blocke | 2014 |
Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Digitalis; Disopyramide; Drug Interactions; Encainide; | 1986 |
3 trials available for disopyramide and Cardiac Failure
| Article | Year |
|---|---|
Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia.
Topics: Aged; Clinical Trials as Topic; Coronary Disease; Disopyramide; Drug Evaluation; Heart Failure; Huma | 1977 |
Clinical studies of Norpace (Part IV).
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Clinical Trials as T | 1975 |
Clinical studies of Norpace (Part VI).
Topics: Adult; Anti-Arrhythmia Agents; Anticoagulants; Arrhythmias, Cardiac; Bradycardia; Clinical Trials as | 1975 |
23 other studies available for disopyramide and Cardiac Failure
| Article | Year |
|---|---|
[Evaluation of Disopyramide Efficacy for Refractory Syncope in Heart Failure with Preserved Ejection Fraction Using Holter Electrocardiography: A Case Report].
Topics: Aged, 80 and over; Disopyramide; Electrocardiography, Ambulatory; Heart Failure; Humans; Male; Strok | 2022 |
Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3.
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Disopyramide; Heart Failure; Humans; Sequoia | 2023 |
[Pharmacotherapy of paroxysmal tachycardia].
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Atrial Flutter; Digitalis Glycosides; Disopyramide | 1983 |
Disopyramide-induced ventricular tachycardia.
Topics: Alcoholism; Cardiac Complexes, Premature; Cardiomyopathies; Coronary Disease; Disopyramide; Heart Fa | 1980 |
Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.
Topics: Adult; Aged; Biological Availability; Blood Proteins; Body Weight; Carbon Radioisotopes; Disopyramid | 1984 |
Prediction of response to class I antiarrhythmic drugs during electrophysiologic study of ventricular tachycardia.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Disopyramide; Dose-Response Relationship, Drug; Ele | 1982 |
Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Biological Availability; Disopyramide; Fema | 1981 |
Cardiovascular collapse associated with disopyramide therapy.
Topics: Administration, Oral; Aged; Arrhythmias, Cardiac; Disopyramide; Electrocardiography; Female; Heart A | 1981 |
[Cardiac shock after disopyramide].
Topics: Disopyramide; Heart Block; Heart Failure; Humans; Male; Middle Aged; Pyridines; Shock, Cardiogenic | 1981 |
Congestive heart failure caused by oral disopyramide.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Disopyramide; Female; Heart Failure; Humans | 1980 |
Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure.
Topics: Amiodarone; Anti-Arrhythmia Agents; Disopyramide; Dose-Response Relationship, Drug; Heart Failure; H | 1997 |
Serum alpha 1-acid glycoprotein, sialic acid, and protein binding of disopyramide in normal subjects and cardiac patients.
Topics: Adult; Aged; Disopyramide; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; | 1997 |
Clinical studies of Norpace (Part X).
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Complexes | 1975 |
Complications of disopyramide therapy.
Topics: Bundle-Branch Block; Confusion; Disopyramide; Heart Failure; Humans; Male; Middle Aged; Propranolol; | 1979 |
Cardiogenic shock and disopyramide phosphate.
Topics: Acute Disease; Arrhythmias, Cardiac; Cardiac Output; Disopyramide; Heart Failure; Humans; Kidney Fai | 1979 |
Cardiac consequences and treatment of disopyramide intoxication: experimental evaluation in dogs.
Topics: Animals; Arrhythmias, Cardiac; Disopyramide; Dogs; Dopamine; Electrocardiography; Glucagon; Heart Ar | 1979 |
Therapy with antiarrhythmic drugs.
Topics: Acetylation; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Heart Failure; Humans; Indo | 1978 |
Circulatory effects of intravenous disopyramide in heart failure.
Topics: Blood Pressure; Cardiac Output; Disopyramide; Heart Failure; Heart Rate; Hemodynamics; Humans; Injec | 1976 |
Haemodynamic effects of intravenous disopyramide in heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Disopyramide; Electrocardiography; Female; Heart Failur | 1975 |
Serum alpha-1-acid glycoprotein and protein binding of disopyramide in patients with congestive heart failure.
Topics: Aged; Disopyramide; Heart Failure; Humans; Middle Aged; Orosomucoid; Protein Binding | 1992 |
Results of the treatment of cardiac arrhythmias with Palpitin.
Topics: Adult; Aged; Arrhythmias, Cardiac; Coronary Disease; Disopyramide; Female; Heart Failure; Humans; Hy | 1990 |
Evaluation of the vasodilator vs inotropic effect of milrinone using an animal model of left ventricular failure: reversal of disopyramide depression of the myocardium with milrinone.
Topics: Animals; Cardiac Output; Cardiotonic Agents; Depression, Chemical; Disease Models, Animal; Disopyram | 1987 |
Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure.
Topics: Aged; Disopyramide; Heart Failure; Humans; Kinetics; Metabolic Clearance Rate; Middle Aged; Myocardi | 1985 |